Myomo (MYO) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Myomo Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Myomo is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Myomo's Risk Assessment

For the Medical Devices subindustry, Myomo's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myomo's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Myomo's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Myomo's Risk Assessment falls into.

Myomo (AMEX:MYO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Myomo Risk Assessment Related Terms

Thank you for viewing the detailed overview of Myomo's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Myomo (MYO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Myomo Inc (AMEX:MYO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

0M61:Germany 0M61:Germany

Address

137 Portland Street, 4th Floor, Boston, MA, USA, 02114

Website

https://www.myomo.com

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the device to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).

Executives

Thomas F Kirk	director
Milton Mayo Morris	director	2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Paul R Gudonis	director, officer: Chief Executive Officer	9 HICKORY ROAD, MANCHESTER MA 01944
David A Henry	officer: Chief Financial Officer
Harry Kovelman	officer: Chief Medical Officer	C/O MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Yitzchak Jacobovitz	director	MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Micah Mitchell	officer: Chief Commercial Officer	C/O MYOMO, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02139
Crowley Thomas Aloysius Jr.	director	19 ST CLAIR AV, SPRING LAKE NJ 07762
Cliff Conneighton	officer: Chief Marketing Officer	53 DEPOT ROAD, HOLLS NH 03049
Jonathan Naft	officer: VP, General Manager	C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Brandon M Green	officer: Chief Medical Officer	C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ralph A Goldwasser	officer: Chief Financial Officer	BNN CORP, 150 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Davie Mendelsohn	officer: VP, Sales	C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Steve Sanghi	director	2355 W CHANDLER BLVD, CHANDLER AZ 85224-6199
Amy K. Knapp	director	75 N. MOUNTAIN AVE, MONTCLAIR NJ 07042